Inactive Instrument

Perrigo Company PLC Stock TEL AVIV STOCK EXCHANGE

Equities

IE00BGH1M568

Pharmaceuticals

Sales 2024 * 4.62B 1,664B Sales 2025 * 4.83B 1,739B Capitalization 3.75B 1,349B
Net income 2024 * -74M -26.65B Net income 2025 * 103M 37.09B EV / Sales 2024 * 1.51 x
Net Debt 2024 * 3.21B 1,156B Net Debt 2025 * 3.01B 1,085B EV / Sales 2025 * 1.4 x
P/E ratio 2024 *
-19 x
P/E ratio 2025 *
172 x
Employees -
Yield 2024 *
4.01%
Yield 2025 *
4.27%
Free-Float 99.66%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 55 23-06-29
Director of Finance/CFO 49 22-05-15
Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Chairman 55 20-12-14
Director/Board Member 68 17-02-05
Director/Board Member 67 17-02-05
More insiders
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
More about the company